Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

2-aminoimidazoles collapse mycobacterial proton motive force and block the electron transport chain.

Jeon AB, Ackart DF, Li W, Jackson M, Melander RJ, Melander C, Abramovitch RB, Chicco AJ, Basaraba RJ, Obregón-Henao A.

Sci Rep. 2019 Feb 6;9(1):1513. doi: 10.1038/s41598-018-38064-7.

2.

Analogue synthesis reveals decoupling of antibiofilm and β-lactam potentiation activities of a lead 2-aminoimidazole adjuvant against Mycobacterium smegmatis.

Martin SE, Nguyen CM, Basaraba RJ, Melander C.

Chem Biol Drug Des. 2018 Aug;92(2):1403-1408. doi: 10.1111/cbdd.13208. Epub 2018 May 12.

3.

Topical therapy for refractory rhinosinusitis caused by methicillin-resistant Staphylococcus aureus: First report in a prospective series.

Shikani AH, Khoueir N, Jabra-Rizk MA, Shikani HJ, Basaraba RJ, Leid JG.

Auris Nasus Larynx. 2018 Oct;45(5):994-999. doi: 10.1016/j.anl.2018.01.009. Epub 2018 Feb 6.

PMID:
29426723
4.

2-aminoimidazoles potentiate ß-lactam antimicrobial activity against Mycobacterium tuberculosis by reducing ß-lactamase secretion and increasing cell envelope permeability.

Jeon AB, Obregón-Henao A, Ackart DF, Podell BK, Belardinelli JM, Jackson M, Nguyen TV, Blackledge MS, Melander RJ, Melander C, Johnson BK, Abramovitch RB, Basaraba RJ.

PLoS One. 2017 Jul 27;12(7):e0180925. doi: 10.1371/journal.pone.0180925. eCollection 2017.

5.

Pathology of Tuberculosis: How the Pathology of Human Tuberculosis Informs and Directs Animal Models.

Basaraba RJ, Hunter RL.

Microbiol Spectr. 2017 Jun;5(3). doi: 10.1128/microbiolspec.TBTB2-0029-2016. Review.

PMID:
28597826
6.

Mycobacterial Biofilms: Revisiting Tuberculosis Bacilli in Extracellular Necrotizing Lesions.

Basaraba RJ, Ojha AK.

Microbiol Spectr. 2017 Jun;5(3). doi: 10.1128/microbiolspec.TBTB2-0024-2016. Review.

PMID:
28597824
7.

An aerosol challenge model of tuberculosis in Mauritian cynomolgus macaques.

Sharpe SA, White AD, Sibley L, Gleeson F, Hall GA, Basaraba RJ, McIntyre A, Clark SO, Gooch K, Marsh PD, Williams A, Dennis MJ.

PLoS One. 2017 Mar 8;12(3):e0171906. doi: 10.1371/journal.pone.0171906. eCollection 2017.

8.

The Discovery of 2-Aminobenzimidazoles That Sensitize Mycobacterium smegmatis and M. tuberculosis to β-Lactam Antibiotics in a Pattern Distinct from β-Lactamase Inhibitors.

Nguyen TV, Blackledge MS, Lindsey EA, Minrovic BM, Ackart DF, Jeon AB, Obregón-Henao A, Melander RJ, Basaraba RJ, Melander C.

Angew Chem Int Ed Engl. 2017 Mar 27;56(14):3940-3944. doi: 10.1002/anie.201612006. Epub 2017 Mar 1.

9.

A model of type 2 diabetes in the guinea pig using sequential diet-induced glucose intolerance and streptozotocin treatment.

Podell BK, Ackart DF, Richardson MA, DiLisio JE, Pulford B, Basaraba RJ.

Dis Model Mech. 2017 Feb 1;10(2):151-162. doi: 10.1242/dmm.025593. Epub 2017 Jan 12.

10.

Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.

Kiran D, Podell BK, Chambers M, Basaraba RJ.

Semin Immunopathol. 2016 Mar;38(2):167-83. doi: 10.1007/s00281-015-0537-x. Epub 2015 Oct 28. Review.

11.

Second generation 2-aminoimidazole based advanced glycation end product inhibitors and breakers.

Furlani RE, Richardson MA, Podell BK, Ackart DF, Haugen JD, Melander RJ, Basaraba RJ, Melander C.

Bioorg Med Chem Lett. 2015 Nov 1;25(21):4820-4823. doi: 10.1016/j.bmcl.2015.06.080. Epub 2015 Jun 29.

12.

Inhibition and breaking of advanced glycation end-products (AGEs) with bis-2-aminoimidazole derivatives.

Richardson MA, Furlani RE, Podell BK, Ackart DF, Haugen JD, Melander RJ, Melander C, Basaraba RJ.

Tetrahedron Lett. 2015;56(23):3406-3409.

13.

Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with Mycobacterium tuberculosis.

Irwin SM, Driver E, Lyon E, Schrupp C, Ryan G, Gonzalez-Juarrero M, Basaraba RJ, Nuermberger EL, Lenaerts AJ.

Dis Model Mech. 2015 Jun;8(6):591-602. doi: 10.1242/dmm.019570. Epub 2015 Mar 30.

14.

Human IL-32 expression protects mice against a hypervirulent strain of Mycobacterium tuberculosis.

Bai X, Shang S, Henao-Tamayo M, Basaraba RJ, Ovrutsky AR, Matsuda JL, Takeda K, Chan MM, Dakhama A, Kinney WH, Trostel J, Bai A, Honda JR, Achcar R, Hartney J, Joosten LA, Kim SH, Orme I, Dinarello CA, Ordway DJ, Chan ED.

Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):5111-6. doi: 10.1073/pnas.1424302112. Epub 2015 Mar 27.

15.

The formation of the granuloma in tuberculosis infection.

Orme IM, Basaraba RJ.

Semin Immunol. 2014 Dec;26(6):601-9. doi: 10.1016/j.smim.2014.09.009. Epub 2014 Oct 22. Review.

PMID:
25453231
16.

Microhemorrhage is an early event in the pulmonary fibrotic disease of PECAM-1 deficient FVB/n mice.

Lishnevsky M, Young LC, Woods SJ, Groshong SD, Basaraba RJ, Gilchrist JM, Higgins DM, Gonzalez-Juarrero M, Bass TA, Muller WA, Schenkel AR.

Exp Mol Pathol. 2014 Aug;97(1):128-36. doi: 10.1016/j.yexmp.2014.06.008. Epub 2014 Jun 24.

17.

Mycobacterium tuberculosis Lsr2 is a global transcriptional regulator required for adaptation to changing oxygen levels and virulence.

Bartek IL, Woolhiser LK, Baughn AD, Basaraba RJ, Jacobs WR Jr, Lenaerts AJ, Voskuil MI.

MBio. 2014 Jun 3;5(3):e01106-14. doi: 10.1128/mBio.01106-14.

18.

Mucosal expression of aquaporin 5 and epithelial barrier proteins in chronic rhinosinusitis with and without nasal polyps.

Shikani AH, Sidhaye VK, Basaraba RJ, Shikani HJ, Alqudah MA, Kirk N, Cope E, Leid JG.

Am J Otolaryngol. 2014 May-Jun;35(3):377-83. doi: 10.1016/j.amjoto.2013.11.011. Epub 2013 Dec 7.

19.

Increased severity of tuberculosis in Guinea pigs with type 2 diabetes: a model of diabetes-tuberculosis comorbidity.

Podell BK, Ackart DF, Obregon-Henao A, Eck SP, Henao-Tamayo M, Richardson M, Orme IM, Ordway DJ, Basaraba RJ.

Am J Pathol. 2014 Apr;184(4):1104-1118. doi: 10.1016/j.ajpath.2013.12.015. Epub 2014 Jan 31.

20.

Expression of antimicrobial drug tolerance by attached communities of Mycobacterium tuberculosis.

Ackart DF, Hascall-Dove L, Caceres SM, Kirk NM, Podell BK, Melander C, Orme IM, Leid JG, Nick JA, Basaraba RJ.

Pathog Dis. 2014 Apr;70(3):359-69. doi: 10.1111/2049-632X.12144. Epub 2014 Feb 24.

21.

Reversal of Mycobacterium tuberculosis phenotypic drug resistance by 2-aminoimidazole-based small molecules.

Ackart DF, Lindsey EA, Podell BK, Melander RJ, Basaraba RJ, Melander C.

Pathog Dis. 2014 Apr;70(3):370-8. doi: 10.1111/2049-632X.12143. Epub 2014 Feb 24.

22.

Mycobacterium tuberculosis pellicles express unique proteins recognized by the host humoral response.

Kerns PW, Ackhart DF, Basaraba RJ, Leid JG, Shirtliff ME.

Pathog Dis. 2014 Apr;70(3):347-58. doi: 10.1111/2049-632X.12142. Epub 2014 Feb 26.

23.

Therapeutic vaccination against relevant high virulence clinical isolates of Mycobacterium tuberculosis.

Shanley CA, Ireton GC, Baldwin SL, Coler RN, Reed SG, Basaraba RJ, Orme IM.

Tuberculosis (Edinb). 2014 Mar;94(2):140-7. doi: 10.1016/j.tube.2013.08.010. Epub 2013 Sep 7.

24.

Early lesions following aerosol infection of rhesus macaques (Macaca mulatta) with Mycobacterium tuberculosis strain H37RV.

Rayner EL, Pearson GR, Hall GA, Basaraba RJ, Gleeson F, McIntyre A, Clark S, Williams A, Dennis MJ, Sharpe SA.

J Comp Pathol. 2013 Nov;149(4):475-85. doi: 10.1016/j.jcpa.2013.05.005. Epub 2013 Jul 21.

PMID:
23880551
25.

Multimodality topical therapy for refractory chronic rhinosinusitis: our experience in thirteen patients with and twelve patients without nasal polyps.

Shikani AH, Kourelis K, Alqudah MA, Shikani HJ, Cope E, Kirk N, Bergstedt D, Basaraba RJ, Leid JG.

Clin Otolaryngol. 2013 Jun;38(3):254-8. doi: 10.1111/coa.12096. No abstract available.

PMID:
23398898
26.

Copper-boosting compounds: a novel concept for antimycobacterial drug discovery.

Speer A, Shrestha TB, Bossmann SH, Basaraba RJ, Harber GJ, Michalek SM, Niederweis M, Kutsch O, Wolschendorf F.

Antimicrob Agents Chemother. 2013 Feb;57(2):1089-91. doi: 10.1128/AAC.01781-12. Epub 2012 Dec 17.

27.

Topical gel therapy for sinonasal polyposis in Samter's triad: preliminary report.

Shikani AH, Kourelis K, Rohayem Z, Basaraba RJ, Leid JG.

Ann Otol Rhinol Laryngol. 2012 Nov;121(11):719-24.

PMID:
23193904
28.

Non-diabetic hyperglycemia exacerbates disease severity in Mycobacterium tuberculosis infected guinea pigs.

Podell BK, Ackart DF, Kirk NM, Eck SP, Bell C, Basaraba RJ.

PLoS One. 2012;7(10):e46824. doi: 10.1371/journal.pone.0046824. Epub 2012 Oct 4.

29.

Beijing sublineages of Mycobacterium tuberculosis differ in pathogenicity in the guinea pig.

Kato-Maeda M, Shanley CA, Ackart D, Jarlsberg LG, Shang S, Obregon-Henao A, Harton M, Basaraba RJ, Henao-Tamayo M, Barrozo JC, Rose J, Kawamura LM, Coscolla M, Fofanov VY, Koshinsky H, Gagneux S, Hopewell PC, Ordway DJ, Orme IM.

Clin Vaccine Immunol. 2012 Aug;19(8):1227-37. doi: 10.1128/CVI.00250-12. Epub 2012 Jun 20.

30.

Uptake and accumulation of oxidized low-density lipoprotein during Mycobacterium tuberculosis infection in guinea pigs.

Palanisamy GS, Kirk NM, Ackart DF, Obregón-Henao A, Shanley CA, Orme IM, Basaraba RJ.

PLoS One. 2012;7(3):e34148. doi: 10.1371/journal.pone.0034148. Epub 2012 Mar 30.

31.

Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis.

Driver ER, Ryan GJ, Hoff DR, Irwin SM, Basaraba RJ, Kramnik I, Lenaerts AJ.

Antimicrob Agents Chemother. 2012 Jun;56(6):3181-95. doi: 10.1128/AAC.00217-12. Epub 2012 Apr 2.

32.

Drug treatment combined with BCG vaccination reduces disease reactivation in guinea pigs infected with Mycobacterium tuberculosis.

Shang S, Shanley CA, Caraway ML, Orme EA, Henao-Tamayo M, Hascall-Dove L, Ackart D, Orme IM, Ordway DJ, Basaraba RJ.

Vaccine. 2012 Feb 21;30(9):1572-82. doi: 10.1016/j.vaccine.2011.12.114. Epub 2012 Jan 11.

33.

Phosphatidylinositol di-mannoside and derivates modulate the immune response to and efficacy of a tuberculosis protein vaccine against Mycobacterium bovis infection.

Parlane NA, Compton BJ, Hayman CM, Painter GF, Basaraba RJ, Heiser A, Buddle BM.

Vaccine. 2012 Jan 11;30(3):580-8. doi: 10.1016/j.vaccine.2011.11.055. Epub 2011 Nov 24.

PMID:
22120192
34.

Vaccines displaying mycobacterial proteins on biopolyester beads stimulate cellular immunity and induce protection against tuberculosis.

Parlane NA, Grage K, Mifune J, Basaraba RJ, Wedlock DN, Rehm BH, Buddle BM.

Clin Vaccine Immunol. 2012 Jan;19(1):37-44. doi: 10.1128/CVI.05505-11. Epub 2011 Nov 9.

35.

Immune Responses of HIV-1 Tat Transgenic Mice to Mycobacterium Tuberculosis W-Beijing SA161.

Honda JR, Shang S, Shanley CA, Caraway ML, Henao-Tamayo M, Chan ED, Basaraba RJ, Orme IM, Ordway DJ, Flores SC.

Open AIDS J. 2011;5:86-95. doi: 10.2174/1874613601105010086. Epub 2011 Oct 19.

36.

Evidence for oxidative stress and defective antioxidant response in guinea pigs with tuberculosis.

Palanisamy GS, Kirk NM, Ackart DF, Shanley CA, Orme IM, Basaraba RJ.

PLoS One. 2011;6(10):e26254. doi: 10.1371/journal.pone.0026254. Epub 2011 Oct 18.

37.

Influence of endurance exercise on serum concentrations of iron and acute phase proteins in racing sled dogs.

Kenyon CL, Basaraba RJ, Bohn AA.

J Am Vet Med Assoc. 2011 Nov 1;239(9):1201-10. doi: 10.2460/javma.239.9.1201.

PMID:
21999792
38.

Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection.

Divanovic S, Sawtell NM, Trompette A, Warning JI, Dias A, Cooper AM, Yap GS, Arditi M, Shimada K, Duhadaway JB, Prendergast GC, Basaraba RJ, Mellor AL, Munn DH, Aliberti J, Karp CL.

J Infect Dis. 2012 Jan 1;205(1):152-61. doi: 10.1093/infdis/jir621. Epub 2011 Oct 11.

39.

Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection.

Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K, Grimsey NJ, Cusens D, Coulter S, Cooper J, Bowden AR, Newton SM, Kampmann B, Helm J, Jones A, Haworth CS, Basaraba RJ, DeGroote MA, Ordway DJ, Rubinsztein DC, Floto RA.

J Clin Invest. 2011 Sep;121(9):3554-63. doi: 10.1172/JCI46095. Epub 2011 Aug 1.

40.

Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells.

Ordway DJ, Shang S, Henao-Tamayo M, Obregon-Henao A, Nold L, Caraway M, Shanley CA, Basaraba RJ, Duncan CG, Orme IM.

Clin Vaccine Immunol. 2011 Sep;18(9):1527-35. doi: 10.1128/CVI.05127-11. Epub 2011 Jul 27.

41.

Increased Foxp3 expression in guinea pigs infected with W-Beijing strains of M. tuberculosis.

Shang S, Harton M, Tamayo MH, Shanley C, Palanisamy GS, Caraway M, Chan ED, Basaraba RJ, Orme IM, Ordway DJ.

Tuberculosis (Edinb). 2011 Sep;91(5):378-85. doi: 10.1016/j.tube.2011.06.001. Epub 2011 Jul 6.

42.

Vaccination of guinea pigs using mce operon mutants of Mycobacterium tuberculosis.

Obregón-Henao A, Shanley C, Bianco MV, Cataldi AA, Basaraba RJ, Orme IM, Bigi F.

Vaccine. 2011 Jun 10;29(26):4302-7. doi: 10.1016/j.vaccine.2011.04.027. Epub 2011 Apr 22.

43.

Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis.

Dharmadhikari AS, Basaraba RJ, Van Der Walt ML, Weyer K, Mphahlele M, Venter K, Jensen PA, First MW, Parsons S, McMurray DN, Orme IM, Nardell EA.

Tuberculosis (Edinb). 2011 Jul;91(4):329-38. doi: 10.1016/j.tube.2011.03.002. Epub 2011 Apr 7.

44.

Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment.

Hoff DR, Ryan GJ, Driver ER, Ssemakulu CC, De Groote MA, Basaraba RJ, Lenaerts AJ.

PLoS One. 2011 Mar 21;6(3):e17550. doi: 10.1371/journal.pone.0017550.

45.

Cigarette smoke increases susceptibility to tuberculosis--evidence from in vivo and in vitro models.

Shang S, Ordway D, Henao-Tamayo M, Bai X, Oberley-Deegan R, Shanley C, Orme IM, Case S, Minor M, Ackart D, Hascall-Dove L, Ovrutsky AR, Kandasamy P, Voelker DR, Lambert C, Freed BM, Iseman MD, Basaraba RJ, Chan ED.

J Infect Dis. 2011 May 1;203(9):1240-8. doi: 10.1093/infdis/jir009. Epub 2011 Feb 28.

PMID:
21357942
46.

Copper resistance is essential for virulence of Mycobacterium tuberculosis.

Wolschendorf F, Ackart D, Shrestha TB, Hascall-Dove L, Nolan S, Lamichhane G, Wang Y, Bossmann SH, Basaraba RJ, Niederweis M.

Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1621-6. doi: 10.1073/pnas.1009261108. Epub 2011 Jan 4.

47.

Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs.

Shang S, Shanley CA, Caraway ML, Orme EA, Henao-Tamayo M, Hascall-Dove L, Ackart D, Lenaerts AJ, Basaraba RJ, Orme IM, Ordway DJ.

Antimicrob Agents Chemother. 2011 Jan;55(1):124-31. doi: 10.1128/AAC.00978-10. Epub 2010 Oct 11.

48.

Multiple M. tuberculosis phenotypes in mouse and guinea pig lung tissue revealed by a dual-staining approach.

Ryan GJ, Hoff DR, Driver ER, Voskuil MI, Gonzalez-Juarrero M, Basaraba RJ, Crick DC, Spencer JS, Lenaerts AJ.

PLoS One. 2010 Jun 14;5(6):e11108. doi: 10.1371/journal.pone.0011108.

49.

Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing.

Sharpe SA, McShane H, Dennis MJ, Basaraba RJ, Gleeson F, Hall G, McIntyre A, Gooch K, Clark S, Beveridge NE, Nuth E, White A, Marriott A, Dowall S, Hill AV, Williams A, Marsh PD.

Clin Vaccine Immunol. 2010 Aug;17(8):1170-82. doi: 10.1128/CVI.00079-10. Epub 2010 Jun 9.

50.

Evaluation of standard chemotherapy in the guinea pig model of tuberculosis.

Ordway DJ, Shanley CA, Caraway ML, Orme EA, Bucy DS, Hascall-Dove L, Henao-Tamayo M, Harton MR, Shang S, Ackart D, Kraft SL, Lenaerts AJ, Basaraba RJ, Orme IM.

Antimicrob Agents Chemother. 2010 May;54(5):1820-33. doi: 10.1128/AAC.01521-09. Epub 2010 Feb 16.

Supplemental Content

Loading ...
Support Center